BRCA2 and ovarian carcinoma: Clinical geneticists use the BWA to calculate BRCA1 and BRCA2 mutation carrier probabilities and breast/ovarian cancer risks, which are used to determine eligibility for genetic testing or to provide individually tailored clinical management.